We are developing the next generation of cancer treatment.
The long term goal of the MUNIN Corporation (“MUNIN”) is the Discovery of Patentable New Medicines through Molecular Genetics Research, from which the company expects to generate profits through the sale of novel proprietary therapeutic products and/or revenue from third parties who license, produce and sell such patent-protected products.
The current key technology platform (protected by 6 issued US and corresponding foreign patents) is the use of the CCN (Cyr61, CTGF, and Nov) family of proteins and their modifiers as novel therapeutics in angiogenesis (the growth of new blood vessels) suppression (for cancer treatment) and activation (for wound healing).
Our company’s research and development team has concluded that the suppression of the Cyr61 clinical target is significantly superior to the targeting of angiogenic growth-factor(s)/receptor(s) or their associated kinase signaling cascades in the development of a broad-spectrum anti-angiogenesis anti-cancer therapeutics. This assessment is predicated on Cyr61’s functional role as the key ultimate tumor-secreted angiogenesis activating effecter molecule employed by multiple tumor angiogenesis signaling pathways (including those targeted by Avastin, Herceptin, Erbitux, Vectibix, and Sunitinib, etc.) to initiate angiogenesis. In striking contrast to the problems encountered in the clinical use of Avastin, Herceptin, and Erbitux, etc., successful suppression of Cyr61 will also close the escape hatch that blood-starved cancer cells can use to avoid being starved into submission. Additionally, anti-hCyr61 hmAbs would also help suppress Cyr61 mediated metastasis and increase tumor sensitivity to standard chemotherapeutic agents (such as Taxol) to improve the effectiveness of such treatments.